Payment overview · 2025
General Payments
$48.36
1 reported records · 1 companies
Healthcare provider profile · identity verified
Mahmud Ul Majeed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GARDEN CITY, KS · NPI 1700393303
Verified facts
What the public records show
CMS Open Payments records show Mahmud Ul Majeed, MD received $48.36 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.36 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.36 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 92 |
| Losartan Potassium | Losartan Potassium | 267 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 52 |
| Gabapentin | Gabapentin | 223 | 57 |
| Metformin Hcl | Metformin Hcl | 216 | 59 |
| Lisinopril | Lisinopril | 204 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 48 |
| Omeprazole | Omeprazole | 176 | 41 |
| Simvastatin | Simvastatin | 159 | 45 |
| Furosemide | Furosemide | 155 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 32 |
| Jardiance | Empagliflozin | 113 | 26 |
| Metformin Hcl Er | Metformin Hcl | 108 | 36 |
| Myrbetriq | Mirabegron | 107 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 26 |
| Ozempic | Semaglutide | 103 | 16 |
| Enalapril Maleate | Enalapril Maleate | 102 | 26 |
| Potassium Chloride | Potassium Chloride | 100 | 30 |
| Warfarin Sodium | Warfarin Sodium | 98 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 20 |
| Montelukast Sodium | Montelukast Sodium | 96 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 24 |
| Eliquis | Apixaban | 92 | 15 |
| Calcitriol | Calcitriol | 90 | 18 |
| Finasteride | Finasteride | 86 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 30 |
| Xarelto | Rivaroxaban | 79 | 12 |
| Farxiga | Dapagliflozin Propanediol | 77 | 11 |
| Tramadol Hcl | Tramadol Hcl | 77 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 64 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 15 |
| Carvedilol | Carvedilol | 62 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 59 | suppressed |
| Spironolactone | Spironolactone | 58 | 18 |
| Donepezil Hcl | Donepezil Hcl | 56 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 14 |
| Nifedipine Er | Nifedipine | 52 | 11 |
| Novolog Flexpen | Insulin Aspart | 52 | 17 |
| Rybelsus | Semaglutide | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 18 |
| Sertraline Hcl | Sertraline Hcl | 50 | 15 |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | 13 |
| Trazodone Hcl | Trazodone Hcl | 48 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Atenolol | Atenolol | 46 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Meloxicam | Meloxicam | 45 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 42 | suppressed |
| Famotidine | Famotidine | 42 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 41 | 11 |
| Allopurinol | Allopurinol | 38 | 13 |
| Amoxicillin | Amoxicillin | 38 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 17 |
| Alprazolam | Alprazolam | 31 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Elinest | Norgestrel-Ethinyl Estradiol | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.36 · 1 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error